BioTime, Inc. (NYSE MKT: BTX) today announced the appointment of Jeffrey Janus as its Vice President of Sales and Marketing. Mr. Janus’ primary focus will be to create, market, and sell research products for BioTime and its subsidiaries in the expanding field of regenerative medicine. Mr. Janus has more than 25 years of experience and a proven track record of creating profitable commercial cell-based business.
“Jeffrey brings tremendous expertise in regenerative medicine, developing and selling research products and reagents, and building business units,” said Michael D. West, PhD, BioTime’s Chief Executive Officer. “We welcome Jeffrey to the BioTime team and look forward to working together with him in expanding our development, marketing, and sale of research products.”
“I am honored and excited to be a part of the BioTime team. It is especially gratifying to be working with BioTime’s partner LifeMap Sciences, Inc. and their unique and powerful on-line integrated database suite for genomic, biomedical and stem cell research. This in-depth database suite, linked to BioTime’s unique PureStem™ lines of standardized human progenitor cells, gives researchers a comprehensive set of tools to study human embryonic development and stem cell biology. Medical research has always depended upon the availability of standardized research products and information, and BioTime and LifeMap have become leaders in consolidating biomedical information with standardized stem cells.”
Mr. Janus was most recently Senior Vice President of Operations at International Stem Cell Corporation (OTCQB: ISCO), where he led the company to discover a process known as parthenogenesis resulting in functional human pluripotent stem cells without the use of fertilized human embryos, and was previously the CEO and founder of Lifeline Cell Technology, LLC, a subsidiary of ISCO. Prior to that, he was a member of the founding team that created Clonetics Corporation and the Clonetics brand of primary human cell products. In addition to his extensive experience in developing and selling cell-based products to the research market, Mr. Janus has led teams of scientists both internally and through external domestic and international collaborations with major academic institutions to conduct research. He has grown several biotechnology companies from the ground up, from licensing or patenting intellectual property, to building teams to develop, manufacture and market products profitably. He has a deep understanding of the process of creating and managing teams and has used the strategic planning process to great success.Mr. Janus has a Masters Degree in Business Administration from California State University, San Diego and a Bachelor Degree in Biochemistry from the University of California at Davis and is a published author of breakthrough papers in the field of parthenogenesis and stem cell research.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV